Contineum Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 5, 2026
CTNM$10.56+2.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(in thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating activities | ||
| Net loss | $(14,456) | $(15,990) |
| Adjustments to reconcile net loss to cash used in operating activities: | ||
| Depreciation and amortization | 83 | 78 |
| Noncash operating lease expense | 624 | 233 |
| Stock-based compensation | 3,823 | 2,569 |
| Accretion of premiums/discounts on marketable securities, net | (395) | (285) |
| Loss on disposal of property and equipment | 2 | 67 |
| Gain on marketable securities | — | (2) |
| Changes in operating assets and liabilities | ||
| Prepaid expenses and other current assets | (1,616) | 203 |
| Accounts payable | 490 | 1,834 |
| Accrued expenses | (3,525) | (2,862) |
| Operating lease liabilities | (1,296) | (257) |
| Net cash used in operating activities | (16,266) | (14,412) |
| Investing activities | ||
| Purchase of property and equipment | (312) | (47) |
| Purchases of marketable securities | (97,117) | (33,691) |
| Sales and maturities of marketable securities | 58,121 | 48,653 |
| Net cash provided by (used in) investing activities | (39,308) | 14,915 |
| Financing activities | ||
| Payments of deferred offering costs | (69) | — |
| Proceeds from exercise of stock options | 198 | 24 |
| Net cash provided by financing activities | 129 | 24 |
| Net increase (decrease) in cash and cash equivalents | (55,445) | 527 |
| Cash and cash equivalents at beginning of period | 75,603 | 21,943 |
| Cash and cash equivalents at end of period | $20,158 | $22,470 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.